X4 Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
XFOR$3.33+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets F-
X4 PHARMACEUTICALS INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $99,216 | $121,718 |
| Marketable securities | 15,000 | — |
| Research and development incentive receivable | 562 | 1,152 |
| Prepaid expenses and other current assets | 7,298 | 5,807 |
| Total current assets | 122,076 | 128,677 |
| Property and equipment, net | 745 | 1,104 |
| Goodwill | 17,351 | 17,351 |
| Right-of-use assets | 5,650 | 7,229 |
| Other assets | 1,436 | 1,225 |
| Total assets | $147,258 | $155,586 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,947 | $7,777 |
| Accrued expenses | 12,816 | 12,034 |
| Current portion of lease liability | 1,099 | 1,198 |
| Current portion of long-term debt | — | 1,315 |
| Total current liabilities | 22,862 | 22,324 |
| Long-term debt, including accretion, net of discount | 54,570 | 32,304 |
| Lease liabilities | 2,612 | 3,603 |
| Warrant liability (Note 4) | 15,683 | 23,131 |
| Other liabilities | 432 | 173 |
| Total liabilities | 96,159 | 81,535 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value. 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 167,434,595 and 121,667,250 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 167 | 122 |
| Additional paid-in capital | 528,956 | 450,786 |
| Accumulated other comprehensive loss | (119) | (119) |
| Accumulated deficit | (477,905) | (376,738) |
| Total stockholders’ equity | 51,099 | 74,051 |
| Total liabilities and stockholders’ equity | $147,258 | $155,586 |
| The accompanying notes are an integral part of these consolidated financial statements | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.